#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial hypertriglyceridaemia Primary hyperoxaluria Hepatobiliary cancer Neurodermatitis General anaesthesia Myeloproliferative neoplasm Autoinflammation with infantile enterocolitis B-cell type acute leukaemia Optic ischaemic neuropathy Loss of consciousness Glioblastoma Acute lymphocytic leukaemia Extraskeletal ossification Lip and/or oral cavity cancer Neuromyelitis optica spectrum disorder More trials…

    Learn about Rare Diseases

    Glycogen storage disease type I – Treatment Factor VIII deficiency – Diagnostics Mantle cell lymphoma – Diagnostics Pituitary-dependent Cushing’s syndrome – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Osteosarcoma – Trials in Disease Metachromatic leukodystrophy – Diagnostics Bronchiolitis obliterans syndrome – Treatment Wolfram syndrome Marfan’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Encorafenib Propranolol Hydrochloride Ruxotemitide Vilobelimab Lysine Aspirin Bortezomib Linagliptin Prasugrel Hydrobromide Leflunomide BLEXIMENIB Acp-204 Tartrate Lbl-007 Immunoglobulin A HYDROGEN PEROXIDE Tas3351 Andexanet Alfa Timrepigene Emparvovec Epcoritamab Sodium Picosulfate Itepekimab More therapies…

    Learn about Your Condition

    Tinnitus Eosinophilic oesophagitis Renal cancer stage IV Tonsillitis Ewing's sarcoma metastatic Mixed-type liposarcoma Aicardi-Goutieres syndrome Breast cancer stage II Neutropenia Pneumonia Colorectal cancer stage IV Fabry's disease Oedema Anogenital dysplasia Optic glioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Marien Hospital Herne Universitätsklinikum der Ruhr-Universität…

Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum

Hoelkeskampring 40, Herne, 44625, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Gilteritinib
    • Midostaurin
    Austria Belgium Finland France Germany Ireland +5

  • Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Gemcitabine Hydrochloride
    • Oxaliplatin
    • Rituximab
    Germany

  • Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Cytarabine
    • Daunorubicin
    Austria Germany

  • Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colon cancer stage II
    • Rectal cancer stage II
    Investigated Drugs:
    • Capecitabine
    Austria Germany

  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium France Germany Italy The Netherlands Spain

  • Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Belgium Bulgaria Czechia Denmark France Germany +9

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Enfortumab Vedotin
    Austria France Germany Greece Italy The Netherlands +3

  • Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    • Obinutuzumab
    • Venetoclax
    Austria Belgium Denmark Finland Germany Ireland +5

  • Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Chlorambucil
    • Rasburicase
    • Obinutuzumab
    Austria Bulgaria Croatia Denmark Estonia France +5
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!